Berlin J A, Colditz G A
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104-6021, USA.
JAMA. 1999 Mar 3;281(9):830-4. doi: 10.1001/jama.281.9.830.
Synthesis of research findings has a long-standing tradition in science. While synthesis is currently required in the US food and drug regulatory process, formal meta-analysis may substitute for a pivotal study or broaden the generalizability of drug efficacy through a preplanned meta-analysis. Preplanned meta-analysis of individual trials with deliberately introduced heterogeneity may maximize the generalizability of results from randomized trials. Combining observational data may help to support an alternative claim or to quantify adverse events. In this setting, methods to address potentially greater sources of bias are required. Overall, meta-analysis adds evidence through the synthesis study findings and permits examination of how treatment effects vary across of subgroups, such as age and sex, and across study settings.
研究结果的综合在科学领域有着悠久的传统。虽然目前在美国食品药品监管过程中需要进行综合分析,但正式的荟萃分析可以替代关键研究,或者通过预先计划的荟萃分析来扩大药物疗效的普遍性。对故意引入异质性的个体试验进行预先计划的荟萃分析,可能会使随机试验结果的普遍性最大化。合并观察性数据可能有助于支持替代性主张或对不良事件进行量化。在这种情况下,需要有方法来处理可能更大的偏倚来源。总体而言,荟萃分析通过综合研究结果增加了证据,并允许考察治疗效果如何因年龄和性别等亚组以及不同研究背景而有所不同。